Rarely, and the far more common effect on digestion runs the opposite way. A systematic review of published cases found exactly thirteen patients with GLP-1-associated gastroparesis, worldwide, ever reported [1]. Two much larger studies found the same drugs associated with fewer coded digestive symptoms in people with irritable bowel syndrome, and with faster — not slower — return of bowel function after spinal surgery. None of the three findings contradicts the others; they describe the same slowing mechanism landing differently depending on the gut it meets.
These drugs work in part by slowing the stomach. That is the mechanism, not a side effect, and it is why a smaller meal feels like enough. This section is about what happens at the far end of that mechanism: the stomach slowing past the point of usefulness and into a diagnosis with a name, an imaging threshold and a treatment pathway of its own. That is a genuinely different question from the ordinary nausea of a dose increase, which the titration page covers and which resolves on its own in most people.
What the published cases show
A systematic review published in 2026 searched PubMed, Embase, Scopus and Web of Science from inception to October 2025 for symptomatic gastroparesis associated with these drugs, and found twelve case reports describing thirteen patients. [1] Most were women, most had type 2 diabetes, and cases occurred in people without diabetes too. Semaglutide was the agent implicated most often, followed by liraglutide, dulaglutide and exenatide — which is roughly the order of how widely each is prescribed, so the ranking tells you less than it appears to.
Symptom onset ranged from hours after a dose to several months into treatment, and it commonly followed either a dose escalation or a restart after a break in therapy — the same two moments that a titration schedule is built around. Reported symptoms were nausea, vomiting, abdominal pain, bloating, early satiety and an inability to keep food down. Imaging or endoscopy often showed a distended stomach still holding its contents, with no mechanical blockage to explain it.
How the diagnosis is actually made
Gastroparesis means delayed gastric emptying with no outlet obstruction, and the standard test is gastric emptying scintigraphy: a labeled meal, then a measurement of how much is still in the stomach four hours later. [2] More than 10% retained, in someone with the symptoms and without a blockage on endoscopy or a CT scan, meets the 2022 American College of Gastroenterology and 2025 American Gastroenterological Association definition. Severity is banded off the same measurement — 10% to 15% is mild, 16% to 35% moderate, and above 35% severe. A carbon-13 breath test is also FDA-approved for the diagnosis.
The condition itself is uncommon. A 2018 claims analysis put the prevalence of documented gastroparesis at 21.5 per 100,000 people, and it runs two to four times more often in women than men. In a US epidemiological study of 82.6 million patients, the causes broke down as type 2 diabetes 51.7%, postsurgical 15%, medication-induced 11.8%, idiopathic 11.3%, type 1 diabetes 5.7% and other 4.5%. Medication-induced is the category these drugs fall into, alongside opioids, cannabis and anticholinergics.
What happened to the reported patients
Management in the published cases was mostly supportive — fluids, antiemetics, and letting the stomach recover. Discontinuing the drug resolved the symptoms in every patient reported. That is the most useful sentence in the review, and it is also the sentence most easily over-read: thirteen people all got better after stopping, which is encouraging and is not the same as a demonstrated reversibility rate. What it does establish is that stopping is the intervention, and that the outcomes published so far have been good.
The general treatment ladder is unchanged by the cause. First-line for mild disease is a small-particle diet low in fat and indigestible fiber, plus antiemetics. Moderate adds prokinetics such as metoclopramide or erythromycin. Severe may need liquid or jejunal feeding, and refractory cases are sometimes treated with a pyloric myotomy or an implanted gastric stimulator. None of that is specific to a GLP-1, and almost none of the published cases needed any of it.
The paradox: irritable bowel symptoms fell, not rose
A matched analysis of people who already had irritable bowel syndrome compared those who started a GLP-1 drug against those who did not, with roughly 6,665 people in each arm[3]. Coded rates were lower on treatment for every symptom measured: chronic diarrhea 8.9% against 10.6%, constipation 19.8% against 22.0%, abdominal pain 31.6% against 35.8%, and bloating 8.3% against 10.9%. Those are the exact symptoms this drug class is best known for causing. The likely explanation is not that IBS improved. Every outcome here is a diagnostic code entered at a visit. Someone who develops new gut symptoms after starting a weight drug may describe them as a side effect rather than as their IBS, so the coded IBS symptom simply does not appear. A real effect from slower gastric emptying is plausible too, and this design cannot tell the two apart. The full breakdown is in the irritable bowel syndrome analysis.
The other paradox: bowel function that returned faster, not slower
A single-center chart review compared 57 patients on a GLP-1 drug against 60 who were not, all having elective spinal fusion surgery [4]. Bowel function returned at a mean of 1.35 days in GLP-1 users against 1.90 days in non-users — faster, not slower, which runs against the mechanism these drugs are known for. Everything else measured was flat: no differences in length of stay, complications, wound problems or patient-reported outcomes. The measurement is soft (a chart note on whether someone passed gas), the groups differed by sex, and 117 patients at one hospital is not a lot. It is a signal worth watching rather than a settled finding, detailed in the bowel-recovery study.
What this means before ordering
The practical content here is narrow and worth stating plainly. Dose increases and restarts are the moments to watch, vomiting that stops you eating is not the ordinary nausea of week three, and the drug is prescribed — which means there is a clinician to call. Whether the seller you are buying from makes that easy is a separate question, and most of them publish very little about it. A discontinuation that goes through a support inbox is a slower discontinuation than one that goes through a prescriber.
There is also a cost consequence that nobody prices. An emptying study, an endoscopy and an unplanned stop all sit outside the monthly figure, and outside the trial protocols that produced the efficacy numbers. Rare events are still expensive when they land on you.